<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883233</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.29085</org_study_id>
    <nct_id>NCT00883233</nct_id>
  </id_info>
  <brief_title>Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in Acne Vulgaris</brief_title>
  <acronym>FREE</acronym>
  <official_title>Efficacy and Safety Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the tolerability of 3 treatment regimens containing
      Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel with that of Adapalene 0.1% /Benzoyl Peroxide
      2.5% Gel standard daily overnight application for 12 weeks in the treatment of acne
      vulgaris. The efficacy of the four treatment regimens will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Local Tolerability Was Analyzed in Terms of Worst Score Post-Baseline.</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Total Sum Score (TSS) is the sum of the 4 local tolerability scores for dryness, erythema, scaling and stinging/burning evaluated at each visit [None=0, Mild=1, Moderate=2 and Severe=3]. In consequence, it ranges from 0 [better outcome] to 12 [worse outcome]and was calculated for each study visit.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil速 Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene BPO Gel standard daily overnight application</intervention_name>
    <description>Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Standard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene-BPO 3-hour daily application before bedtime</intervention_name>
    <description>Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>3-hour before bedtime</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene-BPO Gel every other day application</intervention_name>
    <description>Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>every other day</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene-BPO Gel standard+Cetaphil速 Moisturizing Lotion</intervention_name>
    <description>Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil速 Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Adapalene-BPO Gel with Cetaphil速 Moisturizing Lotion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female Subjects of any race, aged 12 to 35 years inclusive

          -  Subjects with mild or moderate facial acne vulgaris

          -  Subjects with skin phototype I to IV

        Exclusion Criteria:

          -  Subjects with more than 1 nodules or cysts on the face,

          -  Subjects with acne conglobata, acne fulminans, secondary acne (chloracne,
             drug-induced acne, etc.)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Tan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Windsor, ON, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.galderma.com</url>
  </link>
  <verification_date>November 2010</verification_date>
  <lastchanged_date>November 11, 2010</lastchanged_date>
  <firstreceived_date>April 16, 2009</firstreceived_date>
  <firstreceived_results_date>October 11, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Jean-Charles DHUIN Clinical Trial Manager</name_title>
    <organization>Galderma</organization>
  </responsible_party>
  <keyword>Acne</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Emollients</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
